Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias

Leukemia and Lymphoma

Volumn 25, Issue 1-2, 1997, Pages 23-35

  Ragione, Fulvio Della ^a   Iolascon, Achille ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

9p21 chromosomal alterations; Cell cycle; Human leukemias; P16(INK4A) gene; Tumor suppressor genes

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CHROMOSOME 13Q; CHROMOSOME 9P; GENE ACTIVATION; GENE LOCUS; GENE MUTATION; HUMAN; MITOSIS; MULTIGENE FAMILY; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030952947     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709042493     Document Type: Review

References (90)

1. Pardee, A. B. (1989). G1 events and regulation of cell proliferation. Science, 246, 603-608.
2. Grana, X. and Reddy, E. P. (1995). Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11, 211-219.
3. Desai, D., Gu, Y. and Morgan, D. O. (1992). Activation of human cyclin-dependent kinases in vitro. Mol. Biol. Cell., 3, 571-582.
4. Solomon, M. J., Lee, T. and Kirschner, M. W. (1992). Role of phosphorylation in p34CDC2 activation. Mol. Biol. Cell., 3, 12-27.
5. Nurse, P. (1994). Ordering S phase and M phase in the cell cycle. Cell, 79, 547-50.
6. Sherr, C. J (1994). G1 phase progression: cycling on cue. Cell, 79, 551-5.
7. Heichman, K. A. and Roberts, J. M. Rules to replicate by. Cell, 79, 557-62.
8. King, R. W., Jackson, P. K. and Kirschner, M. W. (1994). Mitosis in transition. Cell, 79, 563-71.
9. Hunter, T. and Pines, J. (1994). Cyclins and Cancer II: cyclin D and CDK inhibitors. Come of age. Cell, 79, 573-82.
10. Weinberg, R. A. (1995). The retinoblastoma protein and cell cycle control Cell, 81, 323-330.
11. Wang, J. Y. J., Knudsen, E. S. and Welch, P. J. (1994). The retinoblastoma tumor suppressor protein. Adv Cancer Res., 64, 25-85.
12. Nevins, J. R. (1992). E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science, 258, 424-429.
13. LaThangue, N. B. (1994). DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem. Sci., 19, 108-114.
14. Xiong, Y., Zhang, H. and Beach, D. (1992). D-type cyclins associated with multiple protein kinases and the DNA replication and repair factor PCNA Cell, 71, 505-14.
15. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
16. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. (1993). WAF1, a potent mediator of p53 tumor suppression. Cell, 75, 815-825.
17. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
18. Gu, Y., Turck, C. W. and Morgan, D. O. (1993). Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature, 366, 707-710.
19. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M. and Smith, J. R. (1994). Cloning of senescent cell-derived inhibitors of DMA synthesis using an expression screen. Exp. Cell. Res., 211, 90-98.
20. Jiang, H., Lin, J., Su, Z. Z., Herlyn, M., Kerbel, R. S., Weissman, B. E., Welch, D. R. and Fisher, P. B. (1995). The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene, 10, 1855-1864.
21. kip 1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66.
22. Toyoshima, H. and Hunter, T. (1994). p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78, 67-74.
23. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes and Dev., 9, 639-649.
24. KIP2, a structurally distinct memeber of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes and Dev., 9, 650-662.
25. El-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pientpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W. and Vogelstein, B. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
26. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J W., Elledge, S. J. and Reed, S. I. (1994). p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76, 1013-1023.
27. Li, Y., Jenkins, C. W., Nichols, M. A. and Xiong, Y. (1994). Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene, 9, 2261-2268.
28. Di Leonardo, A., Linke, S. P., Clarkin, K. and Wahl, G. M (1994). DNA damage triggers a prolonged p53-dependent G1 arrest and long term induction of Cipl in normal human fibroblasts. Genes Dev., 8, 2540-2551.
29. Sheikh, M. S., Li, X.-S., Chen, J.-C., Shao, Z.-M., Ordonez, J. V. and Fontana, J. A. (1994). Mechanism of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathway. Oncogene, 9, 3407-3415.
30. Slebos, R. J. C., Lee, M. H., Plunkett, B. S., Kessis, T. D., Williams, B. O., Jacks, T., Hedrick, L., Kastan, M. B. and Cho, K. R (1994). p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human pappillomavirus. Proc. Natl. Acad. Sci. U.S A., 91, 5320-5324.
31. Zhang, W., Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travali, S., Deisseroth, A. B. and Mercer, W. E. (1995). p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55, 668-674.
32. Steiman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A. and El-Houssein, M. E. (1994). Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene, 9, 3389-96.
33. Jiang, H., Lin, J., Su, Z -Z., Collart, F. R., Huberman, E. and Fisher, P. B. (1994). Induction of differentiation in human promyelocitic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9, 3397-3406.
34. Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W. and Elledge, S. J. (1995). p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science, 267, 1024-1027.
35. Waga, S., Hannon, G., Beach, D. and Stillman, B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574-578.
36. Flores-Rozas, H., Kelman, Z., Dean, Pan, Z.-Q., Harper, J. W., Elledge, S. J., O'Donnel, M. and Hurwitz, J. (1994). Cdk-interacting protein-1 [Cip1, Waf1] directly dinds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc. Natl. Acad. Sci. U S.A., 91, 8655-8659.
37. Hall, M., Bates, S. and Peters, G. (1995). Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases. p21 and p27 bind to cyclins. Oncogene, 11, 1581-1588.
38. Reynisdottir, I., Polyak, K., Iavarone, A. and Massague, J. (1995). Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev., 9, 1831-45.
39. Ravitz, M. J., Yan, S., Herr, K. D. and Wenner, C. E. (1995). Transforming growth factor beta-induced activation of cyclin E-cdk2 kinase and down-regulation of p27Kip1 in C3H 10T1/2 mouse fibroblasts. Cancer Res., 55, 1413-1416.
40. Firpo, E. J., Koff, A., Solomon, M. J. and Roberts, J. M. (1994). Inactivation of Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mot. Cell. BioL, 14, 4889-4901.
41. KIP] of cyclin-dependent kinase 4 activation. Cell, 79, 487-496.
42. Nourse, J., Firpo, E., Flanangan, W. M., Coats, S., Polyak, K., Lee, M., Massague, J., Crabtree, G. R. and Roberts, J. M. (1994). Interleukin-2-mediated elimination of the p27KIP1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature, 372, 570-573.
43. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F. and Rolfe, M. (1995). Role of the Ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science, 269, 692-695.
44. Serrano, M., Hannon, G. J. and Beach, D. (1993). A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature, 266, 122-126.
45. Nobon, T., Miura, K., Wu, A., Luis, K., Takabashi, K. and Carson, D. A. (1994). Deletion of the cyclin-dependent kinase 4 inhibitor gene in multiple human cancers. Nature, 368, 753-6.
46. Kamb, A., Gruis, N A., Weaver-Feldhaus, J., Lm, Q., Harshman, K., Tavitgian, S V., Stockert, E., Day, R. S., Johnson, B. E. and Skolnick, M H. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-40.
47. INK4 gene inactivation in the development of human acute lymphoblastic leukemia. Haematologica, 80, 562-573.
48. INK4B is a potential effector of TGF - induced cell cycle arrest. Nature, 371, 257-260.
49. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes and Dev., 8, 2939-2952.
50. INK4. Mol Cell Biol., 15, 2682-2688.
51. Hirai, H., Roussel, M. F., Kato, J.-Y., Ashmun, R. A. and Sherr, C. J. (1995). Novel INK4 proteins, p19, p18. are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell. Biol., 15, 2672-2681.
52. Strauss, M., Lukas, J. and Bartek, J. (1995). Unrestricted cell cycling and cancer. Nature Medicine, 1, 1245-1246.
53. Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., McClure, M., Aitken, J. F., Anderson, D. E., Bergman, W., Frants, R., Goldgar, D. E., Green, A., MacLennan, R., Martin, N. G., Mayer, L. J., Youl, P., Zone, J. J., Skolknick, M. H. and Cannon-Albright, L. A. (1994). Analysis of the p16 gene [CDKN2] as a candidate for the chromosome 9p melanoma susceptibility locus Nature Genet., 8, 22-26.
54. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J. and Kern, S. E. (1994). Frequent somatic mutations and homozygous deletions of the p16 [MTS1] gene in pancreatic adenocarcinoma. Nature Genet., 8, 27-32.
55. Cairns, P., Mao, L., Merlo, Lee, D. J. A., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E. and Sidransky, D. (1994). Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-417.
56. INK4A in human cancer. Proc. Natl. Acad Sci. USA, 91, 11045-11049.
57. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S. and Nakamura, Y. (1994). Frequent somatic mutation of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397.
58. Schimdt, E. E., Ichimura, K., Reifenberger, G. and Collins, V. P. (1994). CDKN2 (p16:MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastoma. Cancer Res., 54, 6321-6324.
59. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A T., Ally, D. S., Sheahan, M. D., Clark, W. H. Jr., Tucker, M. A. and Dracopoli, N. C. (1994). Germline p16 mutations in familial melanoma. Nature Genet., 8, 15-21.
60. Gonzales-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M. and Jones, P. A. (1995). Methylation of the 5′CpG Island of the p16/CDKN2 tumor suppressor gene in normal and transformed human cells correlates with gene silencing. Cancer Res., 55, 4531-4535.
61. Liu, Q., Neuhausen, S., McClure, M., Frye, C., Weaver-Feldhaus, J., Gruis, N. A., Eddington, K., Allalunis-Tumer, M. J., Skolnick, M. H., Fujimura, F. K. and Kamb, A. (1995). CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10, 1061-1067.
62. INK4B/MTS2 and p18 genes in primary and metastatic lung cancer. Cancer Res., 55, 1448-1451.
63. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B. and Sidransky, D. (1995). 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine, 1, 686-692.
64. Walker, D. G., Duan, W., Popovic, E. A., Kaye, A H., Tomlinson, F. H and Lavin, M. (1995). Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytoma. Cancer Res., 55, 20-25.
65. Kawamata, N., Seriu, T., Koeffler, P. H. and Bartram, C. R. (1996). Molecular analysis of the cyclin-dependent kinase inhibitor family: p16 (CDKN2/MTS1/INK4A), p18 (INK4C) and p27(Kip1) genes in neuroblastoma. Cancer, 77, 570-575.
66. Lois, A. F., Cooper, L. T., Geng, Y., Nobori, T. and Carson, D. (1995). Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocytes activation and neuronal differentiation. Cancer Res., 55, 4010-4013.
67. Ogawa, S., Hirano, N., Sato, N., Takahashi, T., Hangaishi, A., Tanaka, K., Kurokawa, M., Tanaka, T., Mitani, K., Yazaki, Y. and Hirai, H. (1994). Homozygous loss of cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood, 84, 2431-2435.
68. INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood, 8, 4036-4044.
69. Quesnel, B., Preudhomme, C., Philippe, N., Vanrumbeke, M., Dervite, I., Lai, J. L., Bauters, F., Watel, E. and Fenaux, P. (1995). p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood, 85, 657-663.
70. Nakamaki, T., Kawamata, N., Schwaller, J., Tobler, A., Fey, M., Pakkala, S., Lee, Y. Y., Kim, B. K., Fukuchi, K., Tsuruoka, N., Kahan, J., Miljer, C. W. and Koeffler, H. P. (1995). Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Brit. J. Haem., 91, 139-149.
71. INK4A) deletions in primary tumor cells of 163 leukemic patients. Blood, 85, 854-862.
72. Stranks, G., Height, S. E., Mitcholl, P., Jadayei, D., Yuille, M. A. R., De Lord, C., Clutterbuck, R. D., Traleaven, J. G., Powles, R. L., Nacheva, E., Oscler, D. G., Karpasa, A . Lanoir, G. M., Smith, S. D., Miller, J. L., Catovsky, D. and Dyer, M. J. S. (1995). Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood, 85, 893-901
73. Dreyling, M. H., Bohlander, S K., Le Beau, M. M and Olopade, O. J. (1995). Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood, 86, 1931-1938.
74. INK4B/MTS2 in human leukemias and lymphomas. Canc. Res., 55, 1436-1440.
75. Sill, H., Goldman, J. M and Cross, N. C. P. (1995). Homozygous deletions of p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood, 85, 2013-2016.
76. Serra, A., Gottardi, E., Della Ragione, F., Saglio, G. and Iolascon, A. (1995). Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukemias. Brit. J. Haem., 91, 625-629.
77. INK4B in non-Hodgkin's Lymphomas. Blood, 86, 1534-1539.
78. Hatta, Y., Hirama, T., Miller, C. W., Yamada, Y., Tomonaga, M. and Koeffler, H P (1995). Homozygous deletion of the p15(MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood, 85, 2699-2704.
79. Fizzotti, M., Cimino, G., Pisegna, S., Alimena, G., Quartarone, C., Mandelli, F., Pellicci, P. G. and Lo Coco, F. (1995). Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood, 85, 2685-2690.
80. INK4 gene deletions in childhood acute lymphoblastic leukemias. Leukemia Res., 11, 883-885.
81. Iolascon, A., Faienza, M., Coppola, B., Delia Ragione, F., Santoro, N. and Schettini, A. (1995). High frequency of homozygous deletions of CDK41 gene in childhood acute lymphoblastic leukemia. Brit. J. Haem., 91, 647-651.
82. INK4 and p18, in childhood T-cell lineage scute lymphoblastic leukemias. Leukemia, 10, 255-260.
83. Takeuchi, S., Bartram, C. R., Seriu, T., Miller, C. W., Tobler, A., Janssen, J. W. G., Reiter, A., Ludwig, W -D., Zimmermann, M., Schwaller, J., Lee, E., Miyoshi, I. and Koeffler, H. P. (1995). Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS2/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood, 86, 755-760.
84. INK4B/ MTS2 in pediatric acute lymphoblastic leukemia. Blood, 65, 2321-2330.
85. INK4B gene deletions in primary leukemias Blood, 86, 311-315.
86. Uchida, T., Watanabe, T., Kinoshita, T., Murate, T., Saito, H. and Hotta, T. (1995). Mutational analysis of the CDKN2(MTS1/p16INK4A) gene in primary B-cell lymphomas. Blood, 86, 2724-2731.
87. Ogawa, S., Hangaishi, A., Miyawaki, S., Hirosawa, S., Miura, Y., Takeyama, K., Kamada, N., Ohtake, S., Ulke, N., Shimazaki, C., Toyama, K., Hirano, M., Mizoguchi, H., Kobayashi, Y., Furusawa, S., Saito, M., Emi, N., Yazaki, Y., Ueda, R and Hirai, H. (1995) Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid rumors in primary human hematopoietic malignancies. Blood, 86, 1548-1556.
88. Sill, H., Aguiar, C. T., Schmidt, H., Hochhaus, A., Goldman, J. M. and Cross. N. C. P. (1996). Mutational analysis of p15 and p16 genes in acute leukaemias. Brit. J. Haem., 92, 681-683.
89. Guidal-Giroux, C., Gerrad, B., Cavé, H., Duval, M., Roharalich, P., Elion, J., Vilmer, E. and Grandchamp, B. (1996). Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias. Brit. J. Haem., 92, 410-419.
90. INK4A gene homozygous deletions in human acute leukaemias with alterations of chromosome 9. Brit. J. Haem., 93, 632-636, 1996.